Scleroderma is a condition that most people have never heard of — until they or someone they know begins living with it. It is rare enough that it rarely appears in mainstream health conversations, yet its impact can be profound: a progressive autoimmune disease in which the immune system mistakenly triggers excessive collagen production, leading to the hardening and tightening of skin and, in many cases, involvement of internal organs including the lungs, heart, kidneys, and digestive system.
An estimated 300,000 Americans are living with scleroderma, according to the Scleroderma Foundation. The majority are women, and diagnosis often comes after years of unexplained symptoms — Raynaud’s phenomenon, fatigue, joint stiffness, and subtle skin changes that may be attributed to stress, ageing, or other conditions before the underlying autoimmune process is identified.
Scleroderma Awareness Month, observed each June, is an opportunity to change that. Not by creating fear, but by building the kind of biological literacy that shortens the distance between early symptoms and informed clinical conversations. Central to that literacy are the autoantibody and inflammation biomarkers associated with systemic sclerosis — measurable signals that, when understood in context, can help individuals advocate more effectively for themselves in medical settings.
What Scleroderma Actually Is
Scleroderma — its name derived from the Greek words for “hard skin” — is the common term for a group of conditions more precisely described as systemic sclerosis (SSc). The word “systemic” is significant: while skin changes are often among the most visible features of the disease, systemic sclerosis involves far more than the surface. It is a connective tissue disease driven by three interrelated processes: immune system activation, vascular damage, and excessive fibrosis.
Autoimmune Activation and Collagen Overproduction
In systemic sclerosis, the immune system produces autoantibodies — antibodies directed against the body’s own proteins, particularly components of the cell nucleus. This autoimmune activity triggers a cascade of events that includes injury to small blood vessels and the activation of cells called fibroblasts, which are responsible for producing collagen.
Normally, collagen production is a tightly regulated process that supports tissue structure and repair. In scleroderma, fibroblast activity becomes dysregulated, generating far more collagen than the body needs. This excess collagen accumulates in the skin and internal organs, causing the progressive thickening and stiffening — fibrosis — that characterises the disease.
The vascular component is also significant. Small blood vessel damage leads to reduced blood flow, particularly to the extremities, contributing to Raynaud’s phenomenon. Over time, vascular changes in the lungs can contribute to pulmonary hypertension, one of the more serious complications associated with systemic sclerosis.
Limited vs. Diffuse Systemic Sclerosis
Systemic sclerosis is broadly divided into two major subtypes, which differ in the extent of skin involvement, the pattern of internal organ involvement, and the specific autoantibodies most commonly associated with each.
Limited cutaneous systemic sclerosis (lcSSc) involves skin thickening that is primarily confined to the hands, face, and forearms — below the elbows and knees. It is often associated with a cluster of features previously known as CREST syndrome (calcinosis, Raynaud’s, oesophageal dysmotility, sclerodactyly, and telangiectasia). Limited scleroderma typically has a slower progression, though it carries a specific risk of pulmonary arterial hypertension over time, which requires monitoring.
Diffuse cutaneous systemic sclerosis (dcSSc) involves more widespread skin thickening, including the trunk and upper arms and legs. It tends to progress more rapidly and carries a higher risk of significant internal organ involvement — particularly interstitial lung disease, kidney involvement (scleroderma renal crisis), and cardiac disease — particularly in the early years after diagnosis.
This distinction between limited and diffuse subtypes is not merely descriptive. Specific autoantibodies are associated with each subtype, making antibody testing a meaningful contributor to clinical characterisation.
Why Scleroderma Awareness Month Matters
The Challenge of Delayed Diagnosis
The Scleroderma Foundation estimates that the average time from first symptom to confirmed diagnosis is two to four years — a delay that mirrors the experience documented in many autoimmune conditions, but which carries particular consequences in systemic sclerosis given the potential for progressive organ involvement during unmonitored periods.
A significant contributor to this delay is the early symptom profile of scleroderma, which is often nonspecific and easy to attribute to other causes. Raynaud’s phenomenon — episodes of colour change in the fingers or toes in response to cold or stress — affects an estimated 10% of the general population in a benign primary form. Distinguishing primary Raynaud’s from Raynaud’s that is an early manifestation of an underlying connective tissue disease like systemic sclerosis is not always straightforward without additional investigation, including autoantibody testing.
Similarly, early fatigue, joint stiffness, and subtle skin thickening may be attributed to rheumatoid arthritis, lupus, or simply the effects of ageing. The consequence of misattribution is that the diagnostic workup that would identify systemic sclerosis — including specific autoantibody testing — may not be initiated until symptoms progress to a stage that would have been better addressed earlier.
Who Is at Higher Risk?
Scleroderma is significantly more common in women than in men — approximately four times more prevalent — and most commonly presents between the ages of 30 and 50. The precise reasons for this female predominance, as in many autoimmune conditions, are not fully understood, though hormonal and genetic factors are thought to play a role.
African American women face a higher risk of developing scleroderma than white women and tend to develop the disease at a younger age and with more severe manifestations, including higher rates of diffuse cutaneous involvement and interstitial lung disease. This disparity reflects both genetic predisposition and, likely, structural inequities in healthcare access that affect both diagnosis timing and quality of ongoing care.
Family history of autoimmune disease — whether scleroderma specifically or conditions such as lupus, Sjögren’s syndrome, or rheumatoid arthritis — is associated with elevated personal risk, reflecting shared genetic underpinnings of autoimmune susceptibility.
Key Biomarkers Linked to Scleroderma
The autoantibody profile of systemic sclerosis is one of its most diagnostically distinctive features. Unlike many autoimmune conditions where autoantibodies are nonspecific, the antibodies associated with scleroderma show a relatively strong correlation with disease subtype and, in some cases, patterns of organ involvement. This makes them particularly valuable as both initial screening tools and as part of longer-term monitoring.
ANA — The Foundational Screening Marker
As with lupus and other autoimmune conditions, the antinuclear antibody (ANA) test is typically the first-line screening marker when connective tissue disease is suspected. ANA detects antibodies directed against components of the cell nucleus and is positive in approximately 90–95% of individuals with systemic sclerosis.
A positive ANA, however, is not specific to scleroderma. It is present in many autoimmune conditions and can also be found at low titres in healthy individuals. When ANA is positive — particularly at higher titres — the next step is to identify the specific antibody pattern, which points toward the most relevant more targeted tests.
The pattern of ANA fluorescence on laboratory testing provides initial guidance: a centromere pattern is associated with limited scleroderma, while a nucleolar or speckled pattern may direct further investigation toward other scleroderma-specific antibodies. This pattern information, along with the titre, helps clinicians determine which specific autoantibodies are worth investigating next.
Anti-Centromere Antibodies
Anti-centromere antibodies (ACA) target proteins associated with the centromere region of chromosomes — the structure that plays a central role in cell division. They are found in approximately 20–40% of individuals with systemic sclerosis and are most strongly associated with limited cutaneous systemic sclerosis.
The presence of anti-centromere antibodies in someone with Raynaud’s phenomenon is considered a meaningful signal that the Raynaud’s may not be primary — that it may instead represent early limited scleroderma or a closely related connective tissue condition. In clinical practice, ACA positivity combined with Raynaud’s and other supportive clinical features substantially raises the probability of limited systemic sclerosis and typically prompts specialist rheumatology referral.
Anti-centromere antibodies are also associated with a specific pattern of complications: while limited scleroderma generally progresses more slowly than the diffuse form, ACA-positive individuals carry a heightened risk of developing pulmonary arterial hypertension over time, which is why regular cardiopulmonary monitoring is recommended for this group.
Anti-Scl-70 and Anti-RNA Polymerase III
Two additional autoantibodies carry particular significance in the characterisation of systemic sclerosis.
Anti-Scl-70 antibodies (also known as anti-topoisomerase I antibodies) target an enzyme involved in DNA replication and repair. They are found in approximately 15–40% of individuals with scleroderma and are most strongly associated with diffuse cutaneous systemic sclerosis and interstitial lung disease. In the context of scleroderma evaluation, a positive anti-Scl-70 result in someone with suggestive symptoms increases clinical suspicion for the diffuse subtype and may prompt earlier pulmonary function testing and chest imaging as part of organ involvement assessment.
Anti-RNA polymerase III antibodies are directed against an enzyme involved in RNA synthesis. They are found in approximately 10–25% of scleroderma patients and are associated with the diffuse cutaneous subtype, rapid skin progression, and a specific risk of scleroderma renal crisis — an uncommon but serious complication involving acute kidney injury and hypertension. The association between anti-RNA polymerase III and renal crisis is considered clinically important enough that blood pressure monitoring is a routine component of management for antibody-positive individuals.
It is worth noting that in systemic sclerosis, these major autoantibodies — anti-centromere, anti-Scl-70, and anti-RNA polymerase III — are largely mutually exclusive. Most individuals with scleroderma will be positive for one of them, or occasionally none, but rarely more than one. This mutual exclusivity adds to their clinical utility in characterising disease subtype.
ESR and CRP — Inflammation Context
General inflammation markers have a more supporting role in scleroderma evaluation compared to the specific autoantibodies, but they contribute useful context.
Erythrocyte sedimentation rate (ESR) may be elevated in active scleroderma, reflecting the systemic inflammatory environment. C-reactive protein (CRP) is less consistently elevated in scleroderma than in some other inflammatory conditions — though it can rise in the context of inflammatory arthritis, myositis (muscle inflammation), or active organ involvement. The combination of elevated inflammatory markers alongside specific autoantibodies and clinical symptoms contributes to the overall clinical picture.
A complete blood count (CBC) may also provide supporting information — anaemia can be present in scleroderma due to several mechanisms including gastrointestinal blood loss or chronic inflammation — and baseline assessment of kidney function and urinalysis is relevant given the renal involvement risk in certain antibody subgroups.
What These Biomarkers Can (and Cannot) Tell You
Screening vs. Confirmed Diagnosis
Scleroderma is one of the conditions most often cited as an example of why autoimmune diagnosis cannot rest on a single laboratory result. Diagnosis of systemic sclerosis is made using classification criteria developed by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR), which incorporate a weighted combination of clinical findings — including skin thickening, Raynaud’s, nailfold capillary changes, pulmonary hypertension, and specific autoantibodies — rather than relying on any one marker alone.
A positive anti-centromere or anti-Scl-70 result in someone without symptoms does not diagnose scleroderma. Equally, a positive ANA alone says very little about whether systemic sclerosis is present. These results are meaningful starting points for clinical investigation, not conclusions.
For someone experiencing Raynaud’s phenomenon who tests positive for anti-centromere antibodies, the appropriate next step is referral to a rheumatologist — not a self-directed management plan based on the antibody result alone.
Predicting Organ Involvement — Clinical Context Matters
While specific autoantibodies do carry associations with particular patterns of organ involvement, the relationship is probabilistic rather than deterministic. Not every anti-Scl-70-positive individual will develop significant interstitial lung disease. Not every anti-RNA polymerase III-positive patient will experience renal crisis. Antibody positivity identifies elevated risk and guides monitoring priorities — it does not predict an individual’s clinical course with certainty.
Nailfold capillaroscopy — a technique in which a clinician examines the tiny blood vessels at the base of the fingernails under magnification — is a valuable clinical tool that complements autoantibody testing in evaluating connective tissue disease risk, particularly in the context of Raynaud’s phenomenon. This is a specialist assessment that cannot be replicated by laboratory testing alone and reflects the multi-modal nature of scleroderma evaluation.
Who May Benefit From Autoantibody Screening
Individuals With Raynaud’s Phenomenon
Raynaud’s phenomenon is characterised by episodic colour changes in the fingers and toes — typically blanching to white, then turning blue, then flushing red — triggered by cold temperatures or emotional stress. Primary Raynaud’s, which occurs without an underlying condition, is common and benign. Secondary Raynaud’s — where the episodes are a manifestation of an underlying connective tissue disease — tends to be more severe and is associated with additional clinical features.
For individuals with Raynaud’s who also experience other symptoms such as joint stiffness, fatigue, skin changes around the fingers, or difficulty swallowing, autoantibody screening — particularly ANA and scleroderma-specific antibodies — is a meaningful clinical conversation to initiate with a healthcare provider. The earlier a potential connective tissue disease is identified, the more opportunity exists for proactive monitoring and specialist input.
Women With Early Skin Tightening
Subtle thickening or tightening of the skin, particularly on the fingers (sometimes described as a “sausage-like” swelling called sclerodactyly) or around the mouth, is among the earlier skin-related signs of systemic sclerosis. This type of change can be easy to dismiss, particularly in its early stages. For women in the 30–50 age range who notice unexplained skin changes alongside other symptoms, raising the question of connective tissue disease with a primary care provider — and requesting autoantibody testing — is an appropriate step toward clarity.
Those With Family History of Autoimmune Disease
As with other autoimmune conditions, a family history of systemic sclerosis or closely related conditions — including lupus, Sjögren’s syndrome, undifferentiated connective tissue disease, or rheumatoid arthritis — is associated with modestly elevated personal risk. For individuals in this category who are experiencing any of the early symptoms described in this article, understanding their autoantibody profile can contribute to more informed and proactive clinical conversations.
Taking Ownership of Your Autoimmune Markers
How Direct-to-Consumer ANA Panels Work
Direct-to-consumer lab testing provides access to ANA screening and, through some platforms, specific autoantibody testing including anti-centromere and anti-Scl-70. After selecting a panel, a blood sample is collected at a certified local laboratory and results are delivered through a secure digital platform.
For individuals in higher-risk categories — women with Raynaud’s phenomenon, unexplained skin changes, or family history of autoimmune disease — DTC testing can provide a starting point for understanding their autoantibody status before or alongside a clinical visit. A positive ANA with a centromere pattern, or a positive anti-Scl-70 result, is a meaningful data point to bring to a primary care provider or rheumatologist.
It is equally important to understand that a negative ANA result does not entirely exclude systemic sclerosis — a small proportion of cases are ANA-negative — and that a positive result without symptoms and clinical context does not constitute a diagnosis. DTC testing is a tool for awareness and informed conversation, not a substitute for rheumatology evaluation.
Monitoring Antibody Patterns Over Time
For individuals already navigating a scleroderma diagnosis or an undifferentiated connective tissue disease, the value of biomarker monitoring lies in tracking trends alongside clinical status. Inflammatory markers such as ESR and CRP, along with kidney function tests and urinalysis, are part of routine monitoring in clinical care for systemic sclerosis. Understanding what these markers measure — and what a change in them may mean — helps individuals participate more actively in their own monitoring conversations.
Scleroderma-specific autoantibodies (anti-centromere, anti-Scl-70, anti-RNA polymerase III) generally remain relatively stable once present and are not routinely re-tested for monitoring purposes in the same way that, for example, anti-dsDNA is tracked in lupus. The focus of longitudinal monitoring in scleroderma tends to be on organ function — pulmonary function tests, echocardiography, kidney function, and skin scoring — rather than antibody levels. DTC awareness testing can support engagement with this broader monitoring picture, but specialist coordination is central to it.
The Role of Rare Disease Awareness in Early Conversations
Rare diseases present a particular challenge in the healthcare landscape: the symptoms that should prompt investigation are often unfamiliar to the individuals experiencing them, and sometimes to the general practitioners who first evaluate them. Scleroderma’s rarity — combined with its early symptom overlap with more common conditions — means that many people spend years in a diagnostic grey zone, aware that something is not right but without a framework for understanding what it might be.
Scleroderma Awareness Month exists to provide that framework. Naming the disease, describing its early signs, and explaining the biomarkers that clinicians use to evaluate it gives patients the language they need to ask better questions and push for more specific answers.
The Scleroderma Foundation has long emphasised that early referral to a specialist who is familiar with systemic sclerosis — ideally a rheumatologist with experience in connective tissue diseases — is one of the most meaningful determinants of care quality. Biomarker literacy supports that referral: an individual who arrives at their appointment knowing what ANA means, asking about anti-centromere testing, and having already documented their Raynaud’s episodes is in a fundamentally better position than one who does not.
This June, if Raynaud’s phenomenon, unexplained skin changes, or a family history of autoimmune disease is part of your story, allow Scleroderma Awareness Month to be the prompt for a conversation you may have been putting off. Bring your symptoms, bring your questions, and if you have biomarker data, bring that too. The earlier the right questions are asked, the earlier the right answers can begin to emerge.
This article is for educational purposes only and does not constitute medical advice. All laboratory results should be interpreted by a qualified healthcare professional in the context of a full clinical evaluation. A positive autoantibody result does not confirm a diagnosis of scleroderma or systemic sclerosis. Direct-to-consumer testing is a health awareness tool and does not diagnose, treat, or prevent any medical condition. Individuals with symptoms suggestive of connective tissue disease should seek evaluation from a qualified healthcare provider, ideally a rheumatologist.
